Gewinn- und Verlustrechnung von Abbott Laboratories

Becton, Dickinson supplies equipment whose demand is soaring due to the rise of GLP-1 medicines. Abbott Laboratories' most important growth driver could benefit from greater adoption of GLP-1 drugs.

Investors can count on these stocks about as much as any to continue their decades-long runs of excellence.

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

These three healthcare stocks provide stability, relatively high dividend yields, and consistent growth.

Abbott Laboratories is upgraded to Buy ahead of Q2 2026 earnings, following a challenging period marked by share price underperformance. The recent acquisition of Exact Sciences adds a high-growth cancer diagnostics vertical, targeting $3bn incremental 2026 sales and potential long-term revenue expansion. 2026 guidance projects 6.5–7.5% organic sales growth and $5.38–$5.58 adjusted EPS, with Exact Sciences acquisition causing $0.20 EPS dilution.

Passive income is characterized by its ability to generate revenue without requiring the earner's continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence.

Abbott Laboratories offers a highly diversified revenue stream across medical devices, diagnostics, nutrition, and generic medicines. Intuitive Surgical maintains a dominant position in robotic-assisted surgery with a high-margin, recurring revenue business model.

Futures are trading lower as we get ready to start the third quarter after a record-setting second quarter that saw the Dow Jones Industrial Average close at 52,317, up 0.26% to finish the venerable index's best first half since 2021, while the Nasdaq finished the session at 26,213, up 1.52% for the tech-heavy index's best quarterly finish since 2020.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

The latest trading day saw Abbott (ABT) settling at $92.71, representing a -1.5% change from its previous close.